

April 17, 2015

**The Dy. General Manager  
Dept. of Corporate Affairs  
The Bombay Stock Exchange Ltd,  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai: 400001**

Dear Sir,

**Subject: Preferential Issue of Equity Shares and convening of Extraordinary General Meeting**

**Ref: Outcome of Board Meeting of Glenmark Pharmaceuticals Ltd. ("Company")**

This is to inform you that the Board of Directors of the Company at its meeting held today, has, *inter alia*,:

- 1) decided to raise funds by way of issue of upto 1,08,00,000 equity shares of Re. 1/- each for cash to Aranda Investments (Mauritius) Pte Ltd, ("Investor"), (a non-promoter company) having its office at c/o CIM Corporate Services Ltd, Les Cascades, Edith Cavell Street, Port Louis, Mauritius, holding SEBI registration number 20120107, having PAN AAFCA0250J and a wholly owned indirect subsidiary of Temasek Holdings (Private) Limited having its registered office at 60B, Orchard Road, #06-18 Tower 2, The Atrium@Orchard, Singapore 238891 on preferential basis at a price of Rs. 875 per equity share aggregating to approximately Rs. 945 Crores, subject to the requisite approvals of the shareholders and any regulatory authorities, as may be required; and
- 2) decided to convene an Extraordinary General Meeting of the Company on Wednesday, 13<sup>th</sup> May'15 at Mumbai for obtaining the Shareholders approval for the preferential issue of equity shares to the Investor as stated herein above.

Accordingly, the relevant date for the pricing of the aforesaid preferential issue of equity shares in terms of Regulation 71 of the Securities and Exchange Board of

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026

CIN No: L24299MH1977PLC019982 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)



India (Issue of Capital and Disclosure Requirements) Regulations, 2009 is April 13, 2015.

The above is for your information and dissemination to the members.

Thanking you.

Yours faithfully,  
**For Glenmark Pharmaceuticals Ltd.**



**Sanjay Kumar Chowdhary**  
**Company Secretary & Compliance Officer**

Tel: 4018 9999 / 4018 9879

Fax No: 4018 9986 (Legal & Secretarial Dept.)